Open AccessLoxiglumide, L-364,718 and L-365,260 Prevent the Inhibition of Spontaneous Acetylcholine Release from the Frontal Cerebral Cortex of Freely Moving Rat Peripherally Administered with Cholecystokinin-8S
Author(s) -
Ikuko Kimura,
Satomi Wakasono,
Masayasu Kimura
Publication year - 1995
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.68.129
Subject(s) - cholecystokinin , antagonist , endocrinology , medicine , acetylcholine , proglumide , receptor antagonist , cholecystokinin receptor , chemistry , microdialysis , cerebral cortex , receptor , pharmacology , central nervous system
We examined the effect of peripheral administration of cholecystokinin (CCK)-8S on spontaneous acetylcholine (ACh) release from the frontal cortex and its prevention by loxiglumide, L-364,718 and L-365,260 in freely moving rats using intracerebral microdialysis. Subcutaneously (s.c.) administered CCK-8S at 10 and 30 micrograms/kg significantly decreased the release of ACh. The inhibitory effect of 10 micrograms/kg (s.c.) CCK-8S was prevented by loxiglumide, a mixed type of CCK-A and -B-receptor antagonist, at 1 mg/kg (intraperitoneal) and 40 micrograms/rat (intracerebroventricular, i.c.v.); L-364,718, a CCK-A-receptor antagonist, at 125 and 250 ng/rat (i.c.v.); and L-365,260, a CCK-B-receptor antagonist at 250 ng/rat (i.c.v.). These results demonstrate that peripherally administered CCK-8S inhibits spontaneous ACh release from the frontal cortex through both central CCK-A (mainly) and -B receptors.